Current Report Filing (8-k)
December 03 2018 - 7:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 3, 2018
SIENNA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38155
|
|
27-3364627
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
30699 Russell Ranch Road, Suite 140
Westlake Village, CA 91362
(Address of principal executive office, including Zip Code)
Registrants telephone number, including area code: (818)
629-2256
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On December 3, 2018, Sienna Biopharmaceuticals, Inc. (the Company) announced
(i) top-line
results from a Phase 2b study of
SNA-120
for the treatment of itch and psoriasis and (ii) results from an exploratory Phase 1/2 study of
SNA-125
for the treatment of atopic dermatitis. Additionally, the Company will be hosting a conference call for analysts and investors to discuss the
top-line
results
utilizing the attached presentation (the Presentation). A copy of the press release and the Presentation are filed as Exhibits 99.1 and 99.2 to this Current Report on Form
8-K,
respectively, and
incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SIENNA BIOPHARMACEUTICALS, INC.
|
|
|
|
|
Date: December 3, 2018
|
|
|
|
By:
|
|
/s/ Timothy K. Andrews
|
|
|
|
|
Name:
|
|
Timothy K. Andrews
|
|
|
|
|
Title:
|
|
General Counsel and Secretary
|
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sienna Biopharmaceuticals (NASDAQ:SNNA)
Historical Stock Chart
From Apr 2023 to Apr 2024